36 results on '"Trigo, Jose Manuel"'
Search Results
2. Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours
3. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
4. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
5. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
6. Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
7. 464 2SMALL (NCT04253145) phase I part: lurbinectidine (LUR) in combination with atezolizumab (ATZ) for second line extensive stage small cell lung cancer (ES-SCLC) patients (pts)
8. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
9. Determination of essential biomarkers in lung cancer: a real-world data study in Spain
10. Determination of essential biomarkers in lung cancer: a real-world data study in Spain.
11. 464 2SMALL (NCT04253145) phase I part: lurbinectidine (LUR) in combination with atezolizumab (ATZ) for second line extensive stage small cell lung cancer (ES-SCLC) patients (pts)
12. The endogenous opioid system: A common substrate in drug addiction
13. Neurobiological mechanisms involved in nicotine dependence and reward: Participation of the endogenous opioid system
14. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)
15. MDMA reinstates cocaine-seeking behaviour in mice
16. Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin
17. Can We Customize Chemotherapy? Individualizing Cytotoxic Regimens in Advanced Non–Small-Cell Lung Cancer
18. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
19. BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.
20. INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors.
21. Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC).
22. Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats
23. Perinatal exposure to Δ9-tetrahydrocannabinol increases presynaptic dopamine D2 receptor sensitivity: a behavioral study in rats
24. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance
25. Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
26. Efficacy of multikinase inhibitors (MKIs) in successive treatment lines of refractory advanced thyroid cancer patients (pts).
27. Retrospective analysis of the safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer (MTC).
28. The HALO study: A phase I-II of the oral HSP90 inhibitor Debio0932 in combination with SOC in first- and second-line therapy of advanced NSCLC.
29. Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours
30. Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin
31. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients
32. Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
33. A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer
34. Perinatal exposure to Δ9-tetrahydrocannabinol increases presynaptic dopamine D2 receptor sensitivity: a behavioral study in rats
35. Perinatal exposure to delta 9-tetrahydrocannabinol increases presynaptic dopamine D2 receptor sensitivity: a behavioral study in rats.
36. Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.